A newly developed pimobendan chewable tablet formulation demonstrated dissolution behavior and pharmacokinetic characteristics comparable to a commercially available formulation in beagle dogs, according to a study published in BMC Veterinary Research.
Pimobendan is an important cardiovascular drug widely used for the long-term management of cardiac diseases in dogs, and chewable tablets have been designed to facilitate oral administration. Because systematic investigations into the formulation development, pharmaceutical properties, stability, and in vivo pharmacokinetic behavior of such chewable tablets have remained limited, researchers aimed to develop and systematically assess a new formulation alongside an existing commercial counterpart.
Pharmaceutical characterization demonstrated that the newly developed chewable tablets met satisfactory standards across essential physical and chemical criteria. The tablets showed satisfactory quality in appearance, weight uniformity, content uniformity, mechanical properties, and moisture content.
In in vitro dissolution testing, the experimental chewable tablets produced a dissolution profile comparable to that of the commercially available product. Specifically, more than 80% of the pimobendan active ingredient was released within 30 minutes.
Stability evaluations revealed that the tablets maintained satisfactory quality when kept under accelerated and long-term storage conditions. However, exposure to light resulted in decreased drug content and reduced 30-minute cumulative performance, demonstrating the specific necessity for light-protective storage.
Following oral administration in beagle dogs, the developed tablets demonstrated rapid absorption and produced in vivo pharmacokinetic profiles comparable to the commercial formulation. The researchers detected no significant differences between the two formulations across major pharmacokinetic parameters, including Cmax, Tmax, Tlast, T1/2, AUC0–∞, Vz/F, CL/F, and MRT0–∞.
The study authors concluded that the formulation was successfully developed with satisfactory pharmaceutical properties and stability, offering useful insights for the preparation and testing of veterinary chewable tablets and representing a potential oral formulation for pimobendan administration in dogs.
Subject of Research: Pharmaceutical development and comparative pharmacokinetic evaluation of pimobendan chewable tablets in beagle dogs
Article Title: Development of pimobendan chewable tablets: pharmaceutical characterization and comparative pharmacokinetic evaluation in beagle dogs
Article References: Li, Z., Ning, J., Lin, C., Xiang, Y., Zhang, Y., Yuan, H., Yang, J., He, R., Yan, Z., & He, J. (2026). Development of pimobendan chewable tablets: pharmaceutical characterization and comparative pharmacokinetic evaluation in beagle dogs. BMC Veterinary Research. https://doi.org/10.1186/s12917-026-06031-4
Image Credits: AI Generated
DOI: 10.1186/s12917-026-06031-4
Keywords: pimobendan, chewable tablets, beagle dogs, pharmacokinetics, canine cardiology, veterinary pharmacology, dissolution testing, drug stability, Development, chewable, tablets, pharmaceutical
News Source: William Thompson. (November 9, 2026). Chewable Pimobendan Tablet Matches Commercial Formulation in Beagle Dog Study. Scienmag.



